Prognostic value of PCSK9 levels in patients with acute coronary syndromes
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prognostic value of PCSK9 levels in patients with acute coronary syndromes
Authors
Keywords
-
Journal
EUROPEAN HEART JOURNAL
Volume 37, Issue 6, Pages 546-553
Publisher
Oxford University Press (OUP)
Online
2015-12-10
DOI
10.1093/eurheartj/ehv637
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Expected impact of applying new 2013 AHA/ACC cholesterol guidelines criteria on the recommended lipid target achievement after acute coronary syndromes
- (2015) Baris Gencer et al. ATHEROSCLEROSIS
- Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes
- (2015) David Nanchen et al. EUROPEAN HEART JOURNAL
- Sweetless'n low LDL-C targets for PCSK9 treatment : Figure 1
- (2015) Baris Gencer et al. EUROPEAN HEART JOURNAL
- Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial
- (2015) Christopher P. Cannon et al. EUROPEAN HEART JOURNAL
- PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future
- (2015) Yuichi J. Shimada et al. EUROPEAN HEART JOURNAL
- Stairs instead of elevators at the workplace decreases PCSK9 levels in a healthy population
- (2015) Christel H. Kamani et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- Reasons for discontinuation of recommended therapies according to the patients after acute coronary syndromes
- (2015) Baris Gencer et al. European Journal of Internal Medicine
- Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland
- (2015) Roland Klingenberg et al. HEART
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
- (2015) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Proprotein convertase subtilisin/kexin type 9 expression is transiently up-regulated in the acute period of myocardial infarction in rat
- (2015) Yan Zhang et al. BMC Cardiovascular Disorders
- PCSK9
- (2014) Nabil G. Seidah et al. CIRCULATION RESEARCH
- Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment
- (2014) Christian Werner et al. VASCULAR PHARMACOLOGY
- Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score
- (2014) Keith A A Fox et al. BMJ Open
- Evidence from a Randomized Trial That Simvastatin, but Not Ezetimibe, Upregulates Circulating PCSK9 Levels
- (2013) Heiner K. Berthold et al. PLoS One
- Third Universal Definition of Myocardial Infarction
- (2012) Kristian Thygesen et al. CIRCULATION
- Positive association of serum prolactin concentrations with all-cause and cardiovascular mortality
- (2012) R. Haring et al. EUROPEAN HEART JOURNAL
- The PCSK9 decade
- (2012) Gilles Lambert et al. JOURNAL OF LIPID RESEARCH
- ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
- (2011) et al. EUROPEAN HEART JOURNAL
- Criteria for Evaluation of Novel Markers of Cardiovascular Risk
- (2009) Mark A. Hlatky et al. CIRCULATION
- Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
- (2008) Janice Mayne et al. Lipids in Health and Disease
- Scaling regression inputs by dividing by two standard deviations
- (2007) Andrew Gelman STATISTICS IN MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started